OCUL
Ocular Therapeutix Inc.
$9.15
+$0.61(+7.14%)
40
Overall
60
Value
10
Tech
50
Quality
Market Cap
$2.11B
Volume
3.38M
52W Range
$6.23 - $16.44
Target Price
$25.64
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $1.9M | $1.9M | $2.0M | $4.2M | $17.4M | $43.5M | $51.5M | $58.4M | $63.7M | $52.0M | ||
| Total Revenue | $1.8M | $1.9M | $2.0M | $4.2M | $17.4M | $43.5M | $51.5M | $58.4M | $63.7M | $52.0M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-443.0K | $-457.0K | $-465.0K | $2.3M | $2.1M | $4.4M | $4.5M | $5.3M | $5.6M | $6.6M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $1.4M | $1.5M | $1.5M | $1.9M | $15.3M | $39.1M | $47.0M | $53.2M | $58.1M | $45.4M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $44.8M | $63.4M | $60.6M | $87.7M | $78.2M | $117.2M | $125.6M | $135.5M | $229.9M | $315.4M | ||
| Research & Development | $27.1M | $30.9M | $36.9M | $41.1M | $28.7M | $50.1M | $53.5M | $61.1M | $127.6M | $197.1M | ||
| Research Expense | $27.1M | $30.9M | $36.9M | $41.1M | $28.7M | $50.1M | $53.5M | $61.1M | $127.6M | $197.1M | ||
| Selling, General & Administrative | $17.7M | $32.5M | $23.7M | $46.6M | $49.5M | $67.1M | $72.1M | $74.5M | $102.2M | $118.3M | ||
| Selling & Marketing Expenses | $6.7M | $17.0M | $4.9M | $24.5M | $26.6M | $35.2M | $39.9M | $40.5M | $41.6M | $53.9M | ||
| General & Administrative Expenses | $11.0M | $15.5M | $18.8M | $22.1M | $22.9M | $31.9M | $32.2M | $33.9M | $60.7M | $64.4M | ||
| Promotion & Advertising | -- | -- | -- | -- | -- | $1.9M | $1.2M | -- | -- | -- | ||
| Salaries & Wages | $-6.0M | $-7.3M | $-7.5M | $8.8M | $7.5M | -- | $17.0M | -- | $33.1M | $43.2M | ||
| Depreciation & Amortization | $-881.0K | $-1.6M | $-2.3M | $2.5M | $2.8M | $2.4M | $2.1M | $3.0M | $3.8M | -- | ||
| Depreciation & Amortization | $-881.0K | $-1.6M | $-2.3M | $2.5M | $2.8M | $2.4M | $2.1M | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | $2.6M | $3.1M | $3.1M | $3.1M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-43.3M | $-61.9M | $-59.1M | $-85.8M | $-62.8M | $-78.0M | $-78.7M | $-82.4M | $-171.8M | $-270.0M | ||
| EBITDA | $-41.6M | $-59.4M | $-55.6M | $-74.1M | $-146.1M | $2.5M | $-64.0M | $-60.3M | $-172.4M | $-246.4M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $1.7M | $1.9M | $1.7M | $6.1M | $6.8M | $6.7M | $7.0M | $11.3M | $13.6M | $11.8M | ||
| Intinc | -- | -- | -- | -- | -- | $4.4M | $4.6M | -- | $20.3M | -- | ||
| Net Non-Operating Interest Income/Expense | $-1.4M | $-1.5M | $-860.0K | $-6.1M | $-6.8M | $-6.7M | $6.2M | $4.2M | $-13.6M | $-11.8M | ||
| Gain on Sale of Securities | -- | -- | -- | $5.5M | $-86.0M | $78.2M | $798.0K | $4.0M | $20.3M | $18.4M | ||
| Other Income/Expense | $1.0K | $-5.0K | -- | $-5.5M | $86.0M | $-78.2M | $13.8M | $-18.2M | $7.7M | $-18.4M | ||
| Other Special Charges | $-1.0K | $5.0K | -- | $-8.0K | -- | $1.0K | $-1.0K | $14.2M | $-27.9M | $29.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | $-2.5M | -- | $2.5M | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | -- | $2.5M | -- | $-2.5M | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-43.0M | $-61.5M | $-58.2M | $-80.3M | $-148.9M | $118.0K | $-64.0M | $-69.4M | $-179.9M | $-254.1M | ||
| Pre-Tax Income | $-44.7M | $-63.4M | $-60.0M | $-86.4M | $-155.6M | $-6.6M | $-84.9M | $-75.5M | $-193.0M | $-263.5M | ||
| NET INCOME | ||||||||||||
| Net Income | $-44.7M | $-63.4M | $-60.0M | $-86.4M | $-155.6M | $-6.6M | $-71.0M | $-80.7M | $-193.5M | $-265.9M | ||
| Net Income (Continuing Operations) | $-44.7M | $-63.4M | $-60.0M | $-86.4M | $-155.6M | $-6.6M | $-71.0M | $-80.7M | $-193.5M | $-265.9M | ||
| Net Income (Discontinued Operations) | $-44.7M | $-63.4M | $-60.0M | $-86.4M | $-155.6M | $-6.6M | $-71.0M | $-80.7M | $-193.5M | $-265.9M | ||
| Net Income (Common Stockholders) | $-44.7M | $-63.4M | $-60.0M | $-86.4M | $-155.6M | $-6.6M | $-71.0M | $-80.7M | $-193.5M | $-265.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-260.8M | ||
| TOTALS | ||||||||||||
| Total Expenses | $44.3M | $62.9M | $60.2M | $90.0M | $80.3M | $121.6M | $130.1M | $140.8M | $235.5M | $322.0M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $24.8M | $28.8M | $38.1M | $45.3M | $60.8M | $76.4M | $76.9M | $79.8M | $158.3M | $187.2M | ||
| Average Shares Outstanding (Diluted) | $24.8M | $28.8M | $38.2M | $45.3M | -- | $82.2M | $82.6M | $85.6M | $158.3M | $187.2M | ||
| Shares Outstanding | $28.8M | $37.3M | $42.8M | $52.6M | $76.1M | $76.8M | $77.5M | $148.6M | $159.0M | $217.7M | ||
| Basic EPS | -- | -- | -- | $-1.91 | $-2.56 | $-0.09 | $-0.92 | $-1.01 | $-1.22 | $-1.42 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-1.91 | $-2.56 | $-0.09 | $-0.92 | $-1.01 | $-1.22 | $-1.42 | ||
| Diluted EPS | $-1.8 | $-2.2 | $-1.57 | $-1.91 | $-2.56 | $-0.98 | $-0.97 | $-1.02 | $-1.22 | $-1.42 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-0.98 | $-0.97 | $-1.02 | $-1.22 | $-1.42 | ||
| OTHER METRICS | ||||||||||||
| Other Gand A | $11.0M | $15.5M | $18.8M | $22.1M | $22.9M | $31.9M | $32.2M | $33.9M | $60.7M | $64.4M | ||
| Rent And Landing Fees | $11.0M | $15.5M | $18.8M | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $6.7M | $17.0M | $4.9M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | $-2.5M | -- | $2.5M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | OCUL | $9.15 | +7.1% | 3.38M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |